过氧化物酶体增殖物激活受体在非酒精性脂肪性肝病发病机制及治疗中的作用
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
作者信息
Kallwitz Eric R, McLachlan Alan, Cotler Scott J
机构信息
Department of Medicine, University of Illinois, 840 S Wood Street, 7th Floor, MC 716, Chicago, IL 60612, USA.
出版信息
World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and can result in nonalcoholic steatohepatitis (NASH) and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators-activated receptors (PPARs) in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPAR alpha and PPAR gamma to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH.
摘要
非酒精性脂肪性肝病（NAFLD）非常普遍，可导致非酒精性脂肪性肝炎（NASH）以及包括肝硬化和肝细胞癌在内的进行性肝病。越来越多的文献表明，过氧化物酶体增殖物激活受体（PPARs）参与了NAFLD的发病机制和治疗。这些核激素受体影响肝脏甘油三酯的积累和胰岛素抵抗。本综述的目的是描述将PPARα和PPARγ与NAFLD/NASH联系起来的数据，并讨论使用PPAR配体治疗NASH的情况。
相似文献
1
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22.
2
[PPAR and NASH].
Nihon Rinsho. 2006 Jun;64(6):1089-94.
3
RLA8-A New and Highly Effective Quadruple PPAR-// and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis.
J Pharmacol Exp Ther. 2019 Apr;369(1):67-77. doi: 10.1124/jpet.118.255216. Epub 2019 Feb 11.
4
Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112. doi: 10.1002/hep.20973.
5
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):731-739. doi: 10.1016/j.jceh.2019.06.004. Epub 2019 Jul 2.
6
Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.
7
From the metabolic syndrome to NAFLD or vice versa?
Dig Liver Dis. 2010 May;42(5):320-30. doi: 10.1016/j.dld.2010.01.016. Epub 2010 Mar 6.
8
The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.
Hepatology. 2014 Nov;60(5):1593-606. doi: 10.1002/hep.27297. Epub 2014 Oct 1.
9
Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
Am J Gastroenterol. 2008 Apr;103(4):1036-42. doi: 10.1111/j.1572-0241.2007.01709.x. Epub 2008 Jan 2.
10
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Expert Opin Pharmacother. 2014 Mar;15(4):493-503. doi: 10.1517/14656566.2014.876992. Epub 2014 Jan 16.
引用本文的文献
1
Fat-1 Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease and Atherosclerosis through Promoting the Nuclear Localization of PPARα in Hamsters.
Research (Wash D C). 2025 Mar 6;8:0577. doi: 10.34133/research.0577. eCollection 2025.
2
Wnt/β-catenin signaling activation promotes lipogenesis in the steatotic liver via physical mTOR interaction.
Front Endocrinol (Lausanne). 2023 Dec 13;14:1289004. doi: 10.3389/fendo.2023.1289004. eCollection 2023.
3
Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.
Nat Commun. 2023 Sep 6;14(1):5451. doi: 10.1038/s41467-023-41061-8.
4
Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations.
PLoS One. 2023 Mar 31;18(3):e0283743. doi: 10.1371/journal.pone.0283743. eCollection 2023.
5
Association of plasma metabolites and diagnostic imaging findings with hepatic lipidosis in bearded dragons (Pogona vitticeps) and effects of gemfibrozil therapy.
PLoS One. 2023 Feb 3;18(2):e0274060. doi: 10.1371/journal.pone.0274060. eCollection 2023.
6
Cold-pressed raspberry seeds oil ameliorates high-fat diet triggered non-alcoholic fatty liver disease.
Saudi Pharm J. 2021 Nov;29(11):1303-1313. doi: 10.1016/j.jsps.2021.09.014. Epub 2021 Oct 6.
7
Beneficial Effects of Echinacoside on Diabetic Cardiomyopathy in Diabetic Mice.
Drug Des Devel Ther. 2020 Dec 18;14:5575-5587. doi: 10.2147/DDDT.S276972. eCollection 2020.
8
Hepatic Transcriptome Analysis Revealing the Molecular Pathogenesis of Type 2 Diabetes Mellitus in Zucker Diabetic Fatty Rats.
Front Endocrinol (Lausanne). 2020 Nov 24;11:565858. doi: 10.3389/fendo.2020.565858. eCollection 2020.
9
Current treatment paradigms and emerging therapies for NAFLD/NASH.
Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892.
10
History of Nonalcoholic Fatty Liver Disease.
Int J Mol Sci. 2020 Aug 16;21(16):5888. doi: 10.3390/ijms21165888.
本文引用的文献
1
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
N Engl J Med. 2007 Jul 5;357(1):28-38. doi: 10.1056/NEJMoa073394. Epub 2007 Jun 5.
2
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22. doi: 10.1152/ajpendo.00340.2006. Epub 2006 Dec 26.
3
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
N Engl J Med. 2006 Nov 30;355(22):2297-307. doi: 10.1056/NEJMoa060326.
4
Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat.
J Biol Chem. 2007 Jan 26;282(4):2483-93. doi: 10.1074/jbc.M610158200. Epub 2006 Nov 23.
5
Prevalence of fatty liver in children and adolescents.
Pediatrics. 2006 Oct;118(4):1388-93. doi: 10.1542/peds.2006-1212.
6
Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha.
Diabetes. 2006 Sep;55(9):2562-70. doi: 10.2337/db05-1322.
7
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Liver Int. 2006 Jun;26(5):613-20. doi: 10.1111/j.1478-3231.2006.01265.x.
8
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Curr Med Res Opin. 2006 May;22(5):873-83. doi: 10.1185/030079906X104696.
9
Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Diabetes Care. 2006 May;29(5):1071-6. doi: 10.2337/diacare.2951071.
10
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1143-51. doi: 10.1111/j.1365-2036.2006.02885.x.
Zotero 插件